Twist Bioscience insider files Form 144 to sell 238 shares on NASDAQ
Rhea-AI Filing Summary
Form 144 notice from Twist Bioscience (TWST) shows an insider sale filing for common stock. The filer plans to sell 238 shares via Fidelity Brokerage Services on NASDAQ with an aggregate market value of $6,179.48 and an approximate sale date of 08/21/2025. The shares were acquired on 08/20/2025 through restricted stock vesting and were received as compensation. The filing lists four prior small common-stock sales by Robert Werner totaling 1,492 shares between 05/21/2025 and 08/04/2025 with gross proceeds reported for each sale. The notice includes the standard certification that the signer is unaware of undisclosed material adverse information.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small, routine insider sale from recently vested restricted stock; no material red flags in the filing.
The filing documents a proposed sale of 238 shares valued at $6,179.48 by an insider through Fidelity on NASDAQ, with acquisition dated 08/20/2025 via restricted stock vesting and payment characterized as compensation. Historical disposals by the same person total 1,492 shares across four trades earlier in 2025, with gross proceeds reported per trade. The sizes and timing suggest routine monetization of vested compensation rather than large-scale divestiture. The filing contains the standard attestation regarding knowledge of material nonpublic information.
TL;DR: Disclosure is complete for Rule 144 purposes; documentation shows compensation-related vesting followed by planned sales.
The Form 144 provides required elements: number of shares, acquisition date and nature (restricted stock vesting), broker details, planned sale date, and prior sales in the past three months. All listed transactions are relatively small in absolute terms and tied to compensation. The signature/attestation language is present. The filing does not disclose any material adverse facts or trading-plan adoption dates.